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###### KEY POINTS

OODs can be identified using coded insurance claims data or electronic health records.Heroin‐involved OODs can be accurately identified.OODs that are suicides/suicide attempts can be identified with adequate accuracy using coded data.OODs involving substance abuse can be identified with adequate accuracy using coded data.Algorithms for classifying suicides/suicide attempts and substance abuse‐involved overdoses can be significantly improved using data derived from natural language processing of clinical text in electronic health records.

1. INTRODUCTION {#pds4772-sec-0007}
===============

Opioid use disorders and fatal and nonfatal opioid‐related overdoses (OODs) are significant public health problems.[1](#pds4772-bib-0001){ref-type="ref"}, [2](#pds4772-bib-0002){ref-type="ref"}, [3](#pds4772-bib-0003){ref-type="ref"}, [4](#pds4772-bib-0004){ref-type="ref"}, [5](#pds4772-bib-0005){ref-type="ref"}, [6](#pds4772-bib-0006){ref-type="ref"}, [7](#pds4772-bib-0007){ref-type="ref"}, [8](#pds4772-bib-0008){ref-type="ref"} Initiatives to reduce prescription opioid‐related risks include clinical guidelines,[9](#pds4772-bib-0009){ref-type="ref"} restricted access to extended‐release/long‐acting (ER/LA) opioids,[10](#pds4772-bib-0010){ref-type="ref"}, [11](#pds4772-bib-0011){ref-type="ref"}, [12](#pds4772-bib-0012){ref-type="ref"} added abuse‐deterrent properties,[13](#pds4772-bib-0013){ref-type="ref"}, [14](#pds4772-bib-0014){ref-type="ref"}, [15](#pds4772-bib-0015){ref-type="ref"} FDA\'s Risk Evaluation and Mitigation Strategies (REMS),[16](#pds4772-bib-0016){ref-type="ref"}, [17](#pds4772-bib-0017){ref-type="ref"}, [18](#pds4772-bib-0018){ref-type="ref"}, [19](#pds4772-bib-0019){ref-type="ref"} opioid management plans,[10](#pds4772-bib-0010){ref-type="ref"}, [20](#pds4772-bib-0020){ref-type="ref"}, [21](#pds4772-bib-0021){ref-type="ref"} and state prescription drug monitoring programs.[22](#pds4772-bib-0022){ref-type="ref"}, [23](#pds4772-bib-0023){ref-type="ref"}, [24](#pds4772-bib-0024){ref-type="ref"} Accurate identification of OODs is essential to quantify the burden of the problem, evaluate risk‐reduction strategies, monitor population‐level outcomes, and improve prevention and quality of care. Furthermore, differentiation of type, such as suicides or heroin‐related overdoses, is needed to target and evaluate specific interventions.

To date, few studies have validated methods used to identify OODs.[25](#pds4772-bib-0025){ref-type="ref"}, [26](#pds4772-bib-0026){ref-type="ref"}, [27](#pds4772-bib-0027){ref-type="ref"}, [28](#pds4772-bib-0028){ref-type="ref"} The purpose of this study was to improve upon and conduct a full validation of a previously developed algorithm to identify overdose events[26](#pds4772-bib-0026){ref-type="ref"} and to develop and validate algorithms that classify types of overdoses (eg, heroin‐related and suicides). The original study was limited in scope, excluding events that occurred within 3 days of surgery, and only assessed positive predictive value (PPV). The present study attempted to improve algorithm performance using (a) additional coded data, including a sample of individuals without identified OODs; (b) data extracted with natural language processing (NLP) of EHR clinical notes; (c) tests in three additional health care systems; and (d) additional performance measures.

2. METHODS {#pds4772-sec-0008}
==========

2.1. Study populations, data sources, and sampling procedures {#pds4772-sec-0009}
-------------------------------------------------------------

Kaiser Permanente Northwest (KPNW) was the primary site for algorithm development and validation; additional sites allowed performance assessment in other data systems. KPNW is an integrated health plan providing comprehensive inpatient and outpatient medical care, including addiction and mental health treatment to members in Oregon and southwest Washington State. KPNW served about 500 000 members at study end and is demographically representative of its service area. The study population included all members with any eligibility from January 1, 2008 to December 31, 2014. Data sources included administrative, clinical, inpatient and outpatient records, claims, and clinical care information received from non‐KPNW settings.

2.2. Samples {#pds4772-sec-0010}
------------

Mutually exclusive samples were constructed for development and validation. Suspected OOD cases composed approximately 56% of each sample, defined by a patient and a point in time (based on ICD9‐CM/ICD10‐CM codes), using the previously developed OOD algorithm (the "OOD algorithm"; Table [1](#pds4772-tbl-0001){ref-type="table"}) and opioid‐related adverse effects codes. The remainder of each sample (approximately 44%) consisted of "at‐risk" individuals likely to have an OOD but for whom no suspected OODs were identified. Individuals at risk were identified using diagnoses commonly comorbid with opioid/other substance use disorders. Diagnoses were chosen on the basis of prior research and existing literature and included the following: (a) substance abuse diagnoses, (b) mental health diagnoses, and (c) diagnoses associated with substance abuse (see [Data S1](#pds4772-supitem-0001){ref-type="supplementary-material"}). Individuals with at least two diagnoses from two categories, without suspected OODs, were considered at risk. We drew stratified random samples of at‐risk individuals, half with 0--29 days\' supply of ER/LA opioids in the prior year, and half with greater than or equal to 30 days\' supply. At‐risk periods were converted to events/nonevents for analyses.

###### 

*ICD‐9* and *ICD‐10* codes used in the initial algorithm to detect opioid overdoses^a^

                                                                                                                *ICD‐9* Code   *ICD‐10* Code
  ------------------------------------------------------------------------------------------------------------- -------------- ---------------
  Poisoning by opium (alkaloids) unspecified                                                                    965.00         
  Poisoning by heroin                                                                                           965.01         
  Poisoning by methadone                                                                                        965.02         
  Poisoning by other opiates and related narcotics                                                              965.09         
  Accidental poisoning by heroin                                                                                E850.0         
  Accidental poisoning by methadone                                                                             E850.1         
  Accidental poisoning by other opiates and related narcotics                                                   E850.2         
  COD: poisoning by opiates and related narcotics[a](#pds4772-note-0004){ref-type="fn"}                         9650           
  COD: poisoning by opium                                                                                                      T40.0
  COD: poisoning by heroin                                                                                                     T40.1
  COD: poisoning by other opioids                                                                                              T40.2
  COD: poisoning by methadone                                                                                                  T40.3
  COD: poisoning by other synthetic narcotic                                                                                   T40.4
  COD: accidental poisoning by and exposure to narcotics and psychodysleptics, not elsewhere classified                        X42
  COD: intentional self‐poisoning by and exposure to narcotics and psychodysleptics, not elsewhere classified                  X62
  COD: undetermined poisoning by and exposure to narcotics and psychodysleptics, not elsewhere classified                      Y12

*Note*. COD: cause of death; ICD‐9/10: International Classification of Diseases, Ninth/Tenth Revision.

Presence of any of these codes was considered indicative of the presence of an OOD.

Though the study period was prior to the nationwide switch to *ICD‐10* diagnostic codes, *ICD‐10* cause‐of‐death codes were in use nationwide throughout the study period.

### 2.2.1. Development sample {#pds4772-sec-0011}

We created the development sample first, using OOD cases previously identified, to maximize information available for development. Cases included events identified using opioid‐related *International Classification of Diseases, Ninth/Tenth Revisions* (*ICD‐9/10*) poisoning codes and opioid‐related adverse effects codes. We included the latter to provide information that would help differentiate OODs from adverse effects. Together, these codes together formed the "suspected overdose" stratum in the sample.

### 2.2.2. Validation sample {#pds4772-sec-0012}

We randomly selected algorithm‐identified OOD events and at‐risk individuals not used in development, proportionate to the number of suspected overdoses (approximately 56%) and at‐risk cases (approximately 44%) in that sample. This "balancing" allowed performance comparisons between development and validation samples. Once development was complete, performance was assessed in the validation sample.

### 2.2.3. Datasets {#pds4772-sec-0013}

The development sample included 1006 events (suspected OODs and at‐risk individuals) from 977 unique people, of which 872 (845 unique people) had EHR information available for chart audit. These 872 events comprised the development dataset. The validation sample included 1696 suspected OOD events and 1136 of which had EHR data available for audit (1100 unique people). These 1136 events formed the validation dataset. Table [2](#pds4772-tbl-0002){ref-type="table"} shows counts of events by type in each sample, the base populations, and sample sizes.

###### 

Development and validation sample descriptions

  Sampling Goal                               Events Identified by:                                       Base Population   Development Sample                          Validation Sample
  ------------------------------------------- ----------------------------------------------------------- ----------------- ------------------------------------------- -------------------------------------------
  Suspected overdose cases                    Opioid poisoning diagnostic codes                           2,271             483                                         848
  Opioid adverse effects diagnostic codes     254                                                         78                103                                         
  At risk for overdose                        Pain, mental health, and substance abuse diagnostic codes   87,550            222 with ≥30 days supply of ER/LA opioids   373 with ≥30 days supply of ER/LA opioids
  223 with ≤30 days supply of ER/LA opioids   372 with ≤30 days supply of ER/LA opioids                                                                                 
  Total                                                                                                   1006              1696                                        

*Note*. ER/LA: extended‐release/long‐acting.

2.3. Portability sites {#pds4772-sec-0014}
----------------------

Kaiser Permanente Washington (KPWA) provides coverage and care to approximately 760 000 individuals in Puget Sound and Spokane. KPWA\'s researchers have access to EHR and claims data from integrated health plan members. Limiting factors for some analyses were lack of chart auditor access to chemical dependency records and hospital data that were restricted to insurance claims.Optum. Data were derived from Optum\'s Integrated Database, which included 12.3 million individuals and links the following data: ambulatory, inpatient, medical claims, prescription, and practice management. Chronologic profiles were created from claims data, EHR structured data, and EHR notes extracted using NLP. Because profile data had limitations, we relaxed criteria for ambiguous cases, allowing "possible" responses for outcomes that were coded yes/no at other sites.Tennessee Medicaid (TennCare) is a managed Medicaid program, covering about 1.2 million Medicaid‐eligible, state residents. TennCare maintains an enrollee registry, records of patient‐provider encounters, pharmacy benefits and usage. Chart audits were restricted to inpatient hospital encounter records to facilitate record access; lack of access to outpatient records, particularly mental health follow‐up after suicides/suicide attempts and outpatient chemical dependency treatment, made these classifications difficult for auditors.

2.4. Chart audit process {#pds4772-sec-0015}
------------------------

Chart audit data were considered the "gold standard" against which algorithm results were compared. Index dates were dates of suspected OODs or, for those at risk, dates of the second qualifying diagnosis. We examined clinical records of at‐risk patients for overdoses for a 2‐year period centered upon the index date (greater than one OOD allowed per person). If no overdoses were found, event dates for at‐risk individuals became dates of qualifying diagnoses; individuals were coded as having no overdose on that date.

At KPNW, professional chart auditors determined whether suspected OODs were actual OODs, and classified confirmed OODs according to whether or not they involved: (a) substance abuse; (b) misuse of prescribed medications (ie, therapeutic use not consistent with directions); (c) heroin; (d) inpatient pain management or anesthesia; (e) patient errors; (f) clinician prescribing errors; (g) alcohol; (h) other substances; and (i) suicide/attempted suicide. We completed 100% duplicate review and resolved discrepancies with review by clinicians and team discussion. Portability sites completed audits using similar procedures, though some adaptations were needed to account for site and data differences. Detailed chart audit procedures, including definitions, are available in [Data S2](#pds4772-supitem-0002){ref-type="supplementary-material"}.

2.5. Algorithm performance standards {#pds4772-sec-0016}
------------------------------------

Algorithm performance was evaluated using sensitivity, specificity, PPV, NPV, and F‐scores. No universal standards exist for sensitivity or specificity because acceptability depends on context and use. We expected OODs and heroin involvement to be readily identifiable, thus set sensitivity and specificity of 85% as acceptable and 90% as excellent for these algorithms. We expected other classifications (abuse, suicides/attempts, misuse, polysubstance involvement, and medication error) to be more difficult, thus set 75% as acceptable for sensitivity/specificity. F‐scores measure the accuracy of the algorithm and vary from 0 to 1, with 1 representing perfect fit. We considered F‐score values of 0.90 or greater to indicate excellent performance. Chi‐square tests assessed differences between performance in development and validation datasets.

2.6. Code‐based algorithm development procedures {#pds4772-sec-0017}
------------------------------------------------

We used the least absolute shrinkage and selection operator (LASSO) regression[29](#pds4772-bib-0029){ref-type="ref"}, [30](#pds4772-bib-0030){ref-type="ref"} to select variables based on predicted probabilities of case status, and classification and regression trees (CART) with random forest (500 trees)[31](#pds4772-bib-0031){ref-type="ref"} to evaluate cutoff values for continuous variables. Variables selected using LASSO were entered into logistic regression analyses to estimate final parameters. Predicted probabilities from logistic regression analyses were used to classify events. Parameters were then applied to the validation dataset and compared with chart audit findings.

### 2.6.1. OOD algorithm {#pds4772-sec-0018}

We began by forcing the *ICD‐9/10* codes from our prior algorithm[26](#pds4772-bib-0026){ref-type="ref"} into the model (Table [1](#pds4772-tbl-0001){ref-type="table"}), then tested the following additional variables: prescribed opioids in the 9 months prior to index date (immediate release \[IR\], ER/LA, or both); substance abuse diagnoses; opioid withdrawal diagnoses; weight change; and hospitalizations. None improved performance. The best fitting model used a binary variable coded "1" if any *ICD‐9/10* codes listed in Table [1](#pds4772-tbl-0001){ref-type="table"} were found.

### 2.6.2. OODs with heroin involvement {#pds4772-sec-0019}

Among chart‐audit‐confirmed OODs in the development sample (n = 423), codes shown in Table [3](#pds4772-tbl-0003){ref-type="table"} were tested to predict heroin involvement. The best fitting model performed well, and used a binary variable coded "1" if E965.01, E850.0, or T40.1 were present.

###### 

*ICD‐9* and *ICD‐10* codes tested in the model to predict if an opioid overdose was related to heroin

  --------- --------------------------------------------------------------------
  E950.0    Suicide and self‐inflicted poisoning by solid or liquid substances
  E965.01   Poisoning by heroin
  E850.0    Accidental poisoning by heroin
  T40.1     COD: poisoning by heroin
  --------- --------------------------------------------------------------------

*Note*. COD: cause of death; ICD‐9/10: International Classification of Diseases, Ninth/Tenth Revision.

### 2.6.3. Suicides/suicide attempt‐related OODs {#pds4772-sec-0020}

We modeled overdoses in the development sample (n = 423) according to whether or not they were suicides/attempted suicides (see Tables [4](#pds4772-tbl-0004){ref-type="table"} and [5](#pds4772-tbl-0005){ref-type="table"} for codes evaluated). The initial model assessed predictors identified in the Mental Health Research Network\'s work predicting suicides/suicide attempts.[32](#pds4772-bib-0032){ref-type="ref"} We created a binary variable if any suicide‐related codes in Table [4](#pds4772-tbl-0004){ref-type="table"} were present, binary variables for single or multiple episode depression diagnoses, and interaction terms for suicide and recurrent depression. Next, we tested diagnoses for alcohol use disorders, anxiety disorders, bipolar disorders, tobacco and drug use disorders, other psychoses, and schizophrenia spectrum disorders (Table [5](#pds4772-tbl-0005){ref-type="table"}). The best fitting model included main effects for suicide codes, single episode depression, recurrent depression, alcohol use disorder (AUD), nonalcohol substance use disorder (SUD), and three interaction terms for suicide with multiple episode depression, AUD and SUD.

###### 

*ICD‐9* diagnostic codes evaluated to predict whether or not an opioid overdose was intentional

  Suicide/Suicide Attempt   
  ------------------------- ----------------------------------------------------------------------
  E950.0                    Suicide and self‐inflicted poisoning by solid or liquid substances
  E950.1                    Barbiturates
  E950.2                    Sedatives and hypnotics
  E950.3                    Tranquilizers and other psychotropic agents
  E950.4                    Other specified drugs and medicinal substances
  E950.5                    Unspecified drug or medicinal substance
  E950.9                    Other and unspecified solid and liquid substances
  E956                      Suicide and self‐inflicted injury by cutting and piercing instrument
  E958.8                    Suicide and self‐inflected injury by other specified means
  E958.9                    Suicide and self‐inflicted injury by unspecified means
  V62.84                    Suicidal ideation

  Single Episode Depression   
  --------------------------- ----------------------------------------------------------------------------------------------------
  296.20                      Major depressive affective disorder, single episode, unspecified
  296.22                      Major depressive affective disorder, single episode, moderate
  296.23                      Major depressive affective disorder, single episode, severe, without mention of psychotic behavior

  Multiple Episode Depression   
  ----------------------------- -------------------------------------------------------------------------------------------------------
  296.30                        Major depressive affective disorder, recurrent episode, unspecified
  296.31                        Major depressive affective disorder, recurrent episode, mild
  296.32                        Major depressive affective disorder, recurrent episode, moderate
  296.33                        Major depressive affective disorder, recurrent episode, severe, without mention of psychotic behavior
  296.36                        Major depressive affective disorder, recurrent episode, in full remission

*Note*. ICD‐9: International Classification of Diseases, Ninth Revision.

###### 

Diagnoses tested for predicting suicides/suicide attempts

  Diagnoses                          *ICD‐9* Codes
  ---------------------------------- -----------------------------------------------------
  Alcohol use disorders              291.x, 303.x, 305.0
  Anxiety disorders                  300.0, 300.2, 300.3, 309.20, 309.21, 309.24, 309.81
  Bipolar disorders                  296.0, 296.1, 296.4--296.7, 296.80, 296.81, 296.89
  Drug use disorders                 292.x, 304.x, 305.2--305.9
  Other psychoses                    297.1, 297.3, 298.8, 298.9, 301.22
  Schizophrenia spectrum disorders   295.x
  Tobacco use disorder               305.1, 649.0, 989.84, V15.82

*Note*. ICD‐9: International Classification of Diseases, Ninth Revision.

### 2.6.4. Substance use involved unintentional OODs {#pds4772-sec-0021}

For unintentional overdoses (n = 268), we developed an algorithm to detect substance abuse involvement, using logistic regression to evaluate diagnostic codes listed in Table [6](#pds4772-tbl-0006){ref-type="table"}. The final model included two terms: (a) a binary indicator of substance abuse coded "1" if any *ICD‐9* code related to heroin was present, or if there were no dispenses for an ER/LA or IR opioid in the year prior to the overdose (including the event date), and (b) indication of opioid abuse from *ICD‐9* codes in the 2 years prior to the event.

###### 

Diagnoses and other variables tested for identifying substance abuse involvement in opioid‐related overdoses

  Diagnoses and Other Variables                                                                                                                                                                                                                                 *ICD‐9* and *ICD‐10* Codes
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------
  Poisoning by heroin                                                                                                                                                                                                                                           965.01
  Accidental poisoning by heroin                                                                                                                                                                                                                                E850.0
  Poisoning by heroin                                                                                                                                                                                                                                           T40.1(COD)
  Poisoning by opium (alkaloids), unspecified                                                                                                                                                                                                                   965.00
  Poisoning by methadone                                                                                                                                                                                                                                        965.02
  Poisoning by other opiates/narcotics                                                                                                                                                                                                                          965.09
  Opioid dependence                                                                                                                                                                                                                                             304.00--304.03, 304.70--304.72
  Opioid abuse                                                                                                                                                                                                                                                  305.50--305.53
  Drug use disorders                                                                                                                                                                                                                                            292.x, 304.x, 305.2--305.9
  Alcohol use disorders                                                                                                                                                                                                                                         291.x, 303.x, 305.0
  Tobacco use disorders                                                                                                                                                                                                                                         305.1, 649.0, 989.84, V15.82
  Count of unique opioid prescribers in the 2 years prior to event                                                                                                                                                                                              n/a
  Count of early ER/LA opioid dispenses in the 2 years prior to event (early refill defined as two consecutive fills of an ER/LA where the number of days between prescriptions was less than or equal to 85% of the days\' supply in the first prescription)   n/a
  Count of early IR opioid dispenses in 2 years prior to the event                                                                                                                                                                                              n/a
  Medicaid/Medicare dual eligibility                                                                                                                                                                                                                            n/a

*Note*. COD: cause of death; ER/LA: extended‐release/long‐acting; ICD‐9/10: International Classification of Diseases, Ninth/Tenth Revision.

2.7. NLP‐enhanced algorithm development {#pds4772-sec-0022}
---------------------------------------

We attempted to enhance code‐based algorithm performance with indicators extracted using NLP of EHR clinical notes. The companion paper (Hazlehurst et al[33](#pds4772-bib-0033){ref-type="ref"}) provides details about development and validation of NLP‐derived variables. Each NLP‐derived variable was tested using logistic regression analyses to determine whether or not its addition improved performance beyond that of each respective code‐based algorithm. We used DeLong\'s test for two correlated receiver operator curves to compare areas under the curve for code‐based and NLP‐enhanced models.

Table [7](#pds4772-tbl-0007){ref-type="table"} shows definitions of NLP‐derived binary variables to code‐based algorithms for testing. The NLP classification "polysubstance including opioid" was broken into six binary subcomponents: named opioids; general "narcotics"; named opioid‐interacting medications; named recreational/illicit drugs; alcohol; named over‐the‐counter medications. The NLP classification "substance abuse" was broken into two subcomponents: alcohol or substance abuse noted; alcohol presence mentioned.

###### 

Natural language processing (NLP) classifications and their alignment with gold standard chart review

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                     NLP‐only Classification                                                                                                      Chart Review Gold Standard Comparator
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Event type, irrespective of substance involved                                                                                                                                                                     Intentional overdose (suicide/suicide attempt)                                                                               Intentional overdose = clearly or possible

  Unintentional overdose (excludes intentional overdose)                                                                                                                                                             Unintentional overdose                                                                                                       

  Overdose of any type (combines intentional and unintentional overdose)                                                                                                                                             Unintentional overdose or intentional overdose = clearly or possible                                                         

  Adverse drug event (excludes any overdose)                                                                                                                                                                         Adverse drug reaction                                                                                                        

  Substance involved in overdose or adverse drug event                                                                                                                                                               Heroin                                                                                                                       Heroin involved = yes or possible

  NLP identifies an overdose or adverse drug event in combination with heroin, regardless of other opioid or nonopioid prescription or over‐the‐counter medication                                                                                                                                                                                

  Opioid only (excludes heroin)                                                                                                                                                                                      A single opioid event (excludes heroin)                                                                                      

  NLP identifies an overdose or adverse drug event in combination with a named opioid (or generic "narcotic") in the absence of heroin and additional nonopioid prescription or over‐the‐counter medications.                                                                                                                                     

  Polysubstance including opioid (excludes heroin)                                                                                                                                                                   A polydrug, opioid event (excludes heroin)                                                                                   

  NLP identifies an overdose or adverse drug event in combination with a named opioid (or generic "narcotic") AND additional nonopioid prescription or over‐the‐counter medications, but in the absence of heroin.                                                                                                                                

  Any opioid (excludes heroin, include polysubstance)                                                                                                                                                                A single or polydrug opioid event (excludes heroin)                                                                          

  Substance abuse involved in opioid‐related overdose                                                                                                                                                                Prescription medication abuse (whether prescribed or not)                                                                    Opioid or nonopioid prescription med abuse = yes, AND NOT heroin = yes or possible in an opioid overdose event

  NLP identifies an opioid overdose in combination with abuse of medications (ie, nontherapeutic goals/actions noted about prescription medications), or documented conclusion of abuse by clinician.                                                                                                                                             

  Substance abuse (including alcohol abuse or presence)                                                                                                                                                              Alcohol present = yes in an opioid overdose event                                                                            

  NLP identifies an opioid overdose in combination with notations of alcohol abuse or just alcohol present                                                                                                                                                                                                                                        

  Illicit drug abuse\                                                                                                                                                                                                Abuse of nonprescribed substances = yes in an opioid overdose event                                                          
  NLP identifies an opioid overdose in combination with heroin or other named recreational drugs (marijuana, cocaine, and methamphetamine).                                                                                                                                                                                                       

  Any substance abuse                                                                                                                                                                                                Opioid or nonopioid prescription med or nonprescribed substance abuse or alcohol present = yes in an opioid overdose event   

  Any of the above types of abuse.                                                                                                                                                                                                                                                                                                                

  Patient error in opioid‐related overdose or adverse drug event                                                                                                                                                     Patient error (EXCLUDES ALL ABUSE above)                                                                                     Opioid or nonopioid medication‐taking error = yes AND NOT ABUSE AS DEFINED ABOVE

  NLP identifies an opioid overdose or adverse drug event in combination with mention of mistake/accident in taking medications                                                                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2.8. Portability assessment {#pds4772-sec-0023}
---------------------------

Portability sites contributed data from commercial insurance, Medicaid and integrated health care settings. The OOD algorithm was applied to each site\'s population from 2008 to 2014 (2008‐2013 for TennCare). Classification algorithms were tested at sites with adequate data. At each site, a random sample of approximately 250 suspected OODs was selected for inclusion. The remaining approximately 250 individuals per sample were selected using the same criteria used at KPNW to identify at‐risk individuals. At KPWA, 435/500 cases had EHR information available (159 confirmed OODs); 500 cases were audited at Optum (258 confirmed OODs), and 516 at TennCare (240 OODs).

Classification algorithms demonstrating acceptable performance at KPNW were implemented at portability sites, comparing results with chart audit. Lack of adequate numbers of cases prevented testing some classification algorithms: heroin involvement at TennCare; substance abuse involvement at KPWA (code‐based, NLP‐enhanced). The NLP‐enhanced algorithm for suicides/suicide attempts was only tested at KPWA as other sites did not have NLP capability.

Mean age and sex in development and validation datasets were similar (48.8 and 46.9 years; 39.5% and 39.6% male, respectively). Confirmed OOD prevalence was 48.5% in the development dataset (n = 423) and 53.3% (n = 605) in the validation dataset. The validation dataset had a slightly higher prevalence of heroin‐involved OODs than the development dataset (16.2% vs. 11.8%) and similar prevalence of intentional overdoses (36.6% development and 34.2% validation), and substance use involved unintentional overdoses (41.4% and 43.7%, respectively). The study protocol was reviewed and approved by all sites\' institutional review boards.

3. RESULTS {#pds4772-sec-0024}
==========

Table [8](#pds4772-tbl-0008){ref-type="table"} summarizes algorithm performance in development and validation datasets for algorithms reaching acceptable performance during development. The OOD algorithm performed well: sensitivity (97.2%), specificity (84.6%), PPV (87.4%), and NPV (96.5%). There were no differences between development and validation datasets on sensitivity, PPV, or NPV, though specificity declined. The heroin‐involved classification also performed well in validation: sensitivity was 91.8%, specificity 99.0%, PPV 94.7%, and NPV 98.4%. Some measures of performance (specificity and PPV) were significantly (*P* ≤ 0.018) better in the validation compared with the development dataset (Table [8](#pds4772-tbl-0008){ref-type="table"}).

###### 

Cross validation of models with 95% confidence intervals and significance tests comparing the performance in the two samples

                                                                                Development Dataset   Validation Dataset   *P* Value for the Difference
  ----------------------------------------------------------------------------- --------------------- -------------------- ------------------------------
  Opioid‐related overdose                                                                                                  
  Sensitivity (95% CI)                                                          97.9 (96.0‐99.0)      97.2 (95.5‐98.4)     0.493
  Specificity (95% CI)                                                          88.9 (85.6‐91.6)      84.6 (81.3‐87.5)     0.028
  PPV (95% CI)                                                                  89.2 (86.4‐91.5)      87.4 (85.0‐89.3)     0.3421
  NPV (95% CI)                                                                  97.8 (95.9‐98.8)      96.5 (94.5‐97.8)     0.205
  F‐score                                                                       0.93                  0.92                 
  OOD[a](#pds4772-note-0011){ref-type="fn"} classified as heroin involved                                                  
  Sensitivity (95% CI)                                                          94.0 (83.5‐98.8)      91.8 (84.6‐96.4)     0.635
  Specificity (95% CI)                                                          96.8 (94.5‐98.3)      99.0 (97.7‐99.7)     0.018
  PPV (95% CI)                                                                  79.7 (69.1‐87.3)      94.7 (88.3‐97.7)     0.004
  NPV (95% CI)                                                                  99.2 (97.6‐99.7)      98.4 (97.0‐99.2)     0.330
  F‐score                                                                       0.86                  0.93                 
  OOD classified as suicide/suicide attempt                                                                                
  Sensitivity (95% CI)                                                          77.4 (70.0‐83.7)      70.5 (63.8‐76.7)     0.142
  Specificity (95% CI)                                                          88.1 (83.6‐91.7)      90.2 (86.9‐92.9)     0.380
  PPV (95% CI)                                                                  79.0 (82.8‐84.0)      78.9 (73.3‐83.6)     0.995
  NPV (95% CI)                                                                  87.1 (83.4‐90.1)      85.5 (82.6‐87.9)     0.551
  F‐score                                                                       0.78                  0.74                 
  OOD classified as abuse involved                                                                                         
  Sensitivity (95% CI)                                                          82.0 (73.6‐88.6)      75.3 (68.2‐81.5)     0.184
  Specificity (95% CI)                                                          83.4 (76.7‐88.9)      79.5 (73.6‐84.6)     0.329
  PPV (95% CI)                                                                  77.8 (70.9‐83.4)      74.0 (68.5‐78.9)     0.462
  NPV (95% CI)                                                                  86.8 (81.4‐90.7)      80.5 (76.0‐84.4)     0.117
  F‐score                                                                       0.80                  0.75                 
  Overdose classified as suicide/suicide attempt using NLP‐enhanced algorithm                                              
  Sensitivity (95% CI)                                                          88.4 (82.3‐93.0)      78.7 (72.5‐84.1)     0.016
  Specificity (95% CI)                                                          91.8 (87.8‐94.8)      91.0 (87.7‐93.6)     0.707
  PPV (95% CI)                                                                  86.2 (80.6‐90.3)      81.9 (76.7‐86.2)     0.278
  NPV (95% CI)                                                                  93.2 (89.8‐95.5)      89.2 (86.3‐91.5)     0.079
  F‐score                                                                       0.87                  0.80                 
  Overdose classified as involving abuse using NLP‐enhanced algorithm                                                      
  Sensitivity (95% CI)                                                          90.1 (83.0‐95.0)      80.5 (73.8‐86.1)     0.030
  Specificity (95% CI)                                                          79.6 (72.5‐85.6)      76.3 (70.2‐81.8)     0.449
  PPV (95% CI)                                                                  75.8 (69.5‐81.1)      72.5 (67.4‐77.2)     0.517
  NPV (95% CI)                                                                  91.9 (86.6‐95.2)      83.4 (78.7‐87.3)     0.023
  F‐score                                                                       0.82                  0.76                 

*Note*. NLP: natural language processing; OOD: opioid‐related overdose.

Opioid‐related overdose.

For the classification identifying suicides/suicide attempts, performance was acceptable for the code‐based model in both datasets and did not differ significantly (*P* ≥ 0.142) between the two. Sensitivity was 70.5%, specificity 90.2%, PPV 78.9%, and NPV 85.5% for the coded‐based algorithm.

Performance of the code‐based classification for substance abuse‐involved OODs was also acceptable: Sensitivity was 75.3%, specificity 79.5%, PPV 74.0%, and NPV 80.5%. Performance did not differ between development and validation datasets (*P* ≥ 0.117).

Models classifying opioid misuse, patient medication errors, and polysubstance involvement did not reach acceptable (greater than or equal to 0.75%) levels of sensitivity and specificity so were not validated. We identified few events involving clinician error and few inpatient events making modeling unfeasible for these classifications. For inpatient overdose/oversedation, we adopted a different identification strategy (see Green et al, companion paper[34](#pds4772-bib-0034){ref-type="ref"}).

3.1. NLP‐enhanced models {#pds4772-sec-0025}
------------------------

The addition of NLP variables did not improve performance of the code‐based OOD algorithm or the heroin algorithm, though NLP‐enhanced models outperformed code‐based models for classifying suicides/suicide attempts (sensitivity = 78.7%, specificity = 91.0%, PPV = 81.9%, and NPV = 89.2%) and those involving substance abuse (sensitivity = 80.5%, specificity = 76.3%, PPV = 72.5%, and NPV = 83.4%). Performance declined for the NLP‐enhanced models in the validation dataset compared with the development dataset (Table [8](#pds4772-tbl-0008){ref-type="table"}), but validation results remained above acceptable limits for suicides/suicide attempts and substance abuse‐involved overdoses for sensitivity, specificity, and NPV.

3.2. Algorithm portability performance {#pds4772-sec-0026}
--------------------------------------

Table [9](#pds4772-tbl-0009){ref-type="table"} presents performance across portability sites. The OOD algorithm performed well, with sensitivity greater than 96%, specificity greater than 84%, and F‐scores greater than 0.92. Cross‐site sensitivity for sites with adequate data to test the heroin‐involved classification was greater than 87%, specificity greater than 99%, and F‐scores greater than or equal to 0.90. The code‐based algorithm for suicides/suicide attempts performed equally at KPNW and KPW (F‐scores of 0.74), though there was a decline in sensitivity at Optum and TennCare, likely a result of data limitations. The NLP‐enhanced algorithm for suicides/attempts performed better than the code‐based algorithm and also performed better at KPWA than at KPNW (F‐scores of 0.85 and 0.80, respectively). The substance abuse‐involved algorithm performed poorly at Optum and TennCare. Upon further investigation, it appeared that chart audit determinations for substance abuse‐related OODs at these two sites were made difficult by data limitations.

###### 

Final results of portability assessment of code‐based and NLP‐enhanced algorithms

                                           KPNW   KPW     Optum   TennCare
  ---------------------------------------- ------ ------- ------- ----------
  OOD                                                             
  Sensitivity                              97.2   100.0   96.9    99.2
  Specificity                              84.6   89.2    100.0   92.4
  PPV                                      87.4   84.1    100.0   91.9
  NPV                                      96.5   100.0   96.9    99.2
  F‐score                                  0.92   0.92    0.98    0.95
  Heroin                                                          
  Sensitivity                              91.8   87.5    98.5    N/A
  Specificity                              99.0   99.3    100.0   N/A
  PPV                                      94.7   93.3    100.0   N/A
  NPV                                      98.4   98.5    99.5    N/A
  F‐score                                  0.93   0.90    0.99    N/A
  Suicide/suicide attempt                                         
  Sensitivity                              70.5   74.1    63.2    44.9
  Specificity                              90.2   86.7    91.0    87.1
  PPV                                      78.9   74.1    81.1    64.5
  NPV                                      85.5   86.7    80.1    75.1
  F‐score                                  0.74   0.74    0.67    0.53
  Suicide/suicide attempt---NLP enhanced                          
  Sensitivity                              78.7   81.5    N/A     N/A
  Specificity                              91.0   95.2    N/A     N/A
  PPV                                      81.9   89.8    N/A     N/A
  NPV                                      89.2   90.9    N/A     N/A
  F‐score                                  0.80   0.85    N/A     N/A
  Abuse involved                                                  
  Sensitivity                              75.3   N/A     67.1    41.5
  Specificity                              79.5   N/A     31.9    62.5
  PPV                                      74.0   N/A     46.2    29.0
  NPV                                      80.5   N/A     52.6    74.4
  F‐score                                  0.76   N/A     0.55    0.34

4. DISCUSSION {#pds4772-sec-0027}
=============

The code‐based OOD algorithm, using *ICD‐9* diagnostic codes and death data using *ICD‐10* codes, has excellent performance across health systems, whether applied to EHR‐based databases or commercial or Medicaid claims databases. Few inpatient events were identified using the algorithm, suggesting that it does not confound inpatient overdoses that are typically medically related with accidental or intentional overdoses occurring elsewhere. Given the excellent performance of the code‐based OOD algorithm, the NLP‐enhanced algorithm was unable to improve performance.

In short, our results show that a simple code‐based algorithm can be used to accurately identify overdoses in widely differing settings. Similarly, the code‐based algorithm classifying overdoses as heroin‐involved showed excellent performance across settings when adequate numbers of heroin‐related events were available for testing. As with the OOD algorithm, however, there was little room from improved performance in an NLP‐enhanced model.

Identifying suicides/attempted suicides presented a greater challenge, though the code‐based algorithm performed adequately. Performance was not as good at Optum or TennCare, but PPV and NPV were acceptable in all but TennCare, where reviews were focused on inpatient health care encounters rather than both inpatient and outpatient data. Other sites had access to OOD‐related follow‐up visits that often provided information necessary to determine when an OOD was a suicide/suicide attempt. The NLP‐enhanced algorithm significantly improved performance for detecting suicides/suicide attempts suggesting that including NLP‐derived data from clinical notes is beneficial when available. Performance of the NLP‐enhanced model was good in both sites with the necessary data.

The code‐based algorithm for substance abuse involvement showed reasonable, moderate performance in KPNW, particularly given the complexity of identifying substance abuse with coded data alone. With room for improvement and the likelihood that clinicians document suspicions about substance abuse in clinical notes rather than using diagnostic codes, we expected and found that the NLP‐enhanced algorithm performance was better. Unfortunately, chart auditors did not have access to chemical dependency records at KPWA, preventing detection of adequate numbers of abuse‐related overdoses to test the model there. Nevertheless, results in KPNW suggest that using NLP to identify substance abuse‐involved overdoses will be more fruitful than code‐based algorithms alone.

As a result of limited cases for some classifications, we were unsuccessful with code‐based or NLP‐enhanced models classifying prescription medication misuse or patient errors. Other limitations included that development was based primarily on data extracted from a single integrated health care system. Portability assessments designed to overcome this limitation provide important confirmation for some outcomes but limitations in sample sizes and data sources at portability sites made some comparisons unfeasible. Also, NLP‐enhanced algorithms rely on a specific NLP system (MediClass) for extracting information from clinical notes. Although the "knowledge" used by MediClass is easily extracted for use by other NLP systems, results may not be identical.

5. CONCLUSIONS {#pds4772-sec-0028}
==============

To our knowledge, this work is the most comprehensive validation of algorithms developed to identify and classify OODs. The code‐based OOD algorithm shows excellent performance across different health care systems using *ICD‐9* encounter codes. The same holds true for classifying overdoses involving heroin. Algorithms for identifying opioid‐related suicides/suicide attempts and substance abuse‐involved overdoses perform adequately, particularly given the complexity of identifying these types of OODs. The NLP‐enhanced algorithms for suicides/suicide attempt‐related overdoses and abuse‐related overdoses substantially enhance classification, which should improve ascertainment in settings with NLP capacity. Finally, we used a conservative strategy for evaluating algorithm performance by using an at‐risk sample of noncases. A random sample of the population would likely have resulted in no identified opioid overdoses and in better algorithm performance but would not have allowed us to learn from missed cases as part of algorithm development. Additional research is now needed to translate and assess the algorithms for use with *ICD‐10* encounter data.
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Data S1 Supplement A: ICD‐9 codes used to identify the sample at‐risk for opioid‐related overdoses.
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Click here for additional data file.
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**Data S2** **Supplement B. Chart Audit Procedures**

Figure 1. Overview of general chart audit procedures.

Table 1. Categories used by chart auditors to classify types of opioid‐related overdoses.

**Table 2. Results of chart audits in the KPNW development sample. Includes both suspected overdoses and review of at‐risk individuals.**
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Click here for additional data file.
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